High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 10, Pages 2118-2126
Publisher
American Society of Hematology
Online
2012-07-20
DOI
10.1182/blood-2012-02-411827
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
- (2012) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia
- (2011) A. Kuhnl et al. BLOOD
- Inactivation of LEF1 in T-cell acute lymphoblastic leukemia
- (2010) A. Gutierrez et al. BLOOD
- Rapid identification of IDH1 and IDH2 mutations in acute myeloid leukaemia using high resolution melting curve analysis
- (2010) Sylvie M. Noordermeer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A
- (2010) Richard F. Schlenk et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways
- (2010) A Kohlmann et al. LEUKEMIA
- The Wnt/ -Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
- (2010) Y. Wang et al. SCIENCE
- NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)
- (2009) F. Schneider et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Marked downregulation of the granulopoiesis regulatorLEF1is associated with disease progression in the myelodysplastic syndromes
- (2009) Andrea Pellagatti et al. BRITISH JOURNAL OF HAEMATOLOGY
- ERGExpression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis ofERG, MN1, andBAALCTranscript Levels Using Oligonucleotide Microarrays
- (2009) Klaus H. Metzeler et al. JOURNAL OF CLINICAL ONCOLOGY
- An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
- (2008) L. Bullinger et al. BLOOD
- An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
- (2008) K. H. Metzeler et al. BLOOD
- Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
- (2008) Jinglan Xu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rapid and sensitive screening forCEBPAmutations in acute myeloid leukaemia
- (2008) Tobias Benthaus et al. BRITISH JOURNAL OF HAEMATOLOGY
- Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells
- (2008) Katharina Salome Minke et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis
- (2008) Konstantin Petropoulos et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Analyzing real-time PCR data by the comparative CT method
- (2008) Thomas D Schmittgen et al. Nature Protocols
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now